Wall Street brokerages expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will announce $157.92 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for AMAG Pharmaceuticals’ earnings, with the highest sales estimate coming in at $160.76 million and the lowest estimate coming in at $155.65 million. AMAG Pharmaceuticals posted sales of $127.42 million in the same quarter last year, which suggests a positive year over year growth rate of 23.9%. The firm is scheduled to announce its next earnings report on Tuesday, August 8th.

On average, analysts expect that AMAG Pharmaceuticals will report full year sales of $157.92 million for the current financial year, with estimates ranging from $640.45 million to $655.96 million. For the next fiscal year, analysts expect that the firm will report sales of $553.33 million per share, with estimates ranging from $481.01 million to $620.89 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of $0.09 by $1.15. The business had revenue of $139.47 million during the quarter, compared to analyst estimates of $150.32 million. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. The business’s quarterly revenue was up 27.6% compared to the same quarter last year. During the same period last year, the business earned ($0.22) earnings per share.

AMAG has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued a “hold” rating and set a $23.00 price target on shares of AMAG Pharmaceuticals in a report on Tuesday, May 2nd. TheStreet cut AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Jefferies Group LLC set a $40.00 price target on AMAG Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, April 20th. Cowen and Company cut AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 3rd. Finally, Barclays PLC reissued a “hold” rating and set a $25.00 price target on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $30.00.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 0.58% during mid-day trading on Thursday, reaching $17.40. The company had a trading volume of 86,474 shares. The stock’s market capitalization is $609.78 million. AMAG Pharmaceuticals has a 12-month low of $17.00 and a 12-month high of $36.83. The stock has a 50 day moving average price of $20.79 and a 200-day moving average price of $25.46.

In other news, SVP Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $24.45, for a total value of $46,234.95. Following the sale, the senior vice president now directly owns 36,777 shares of the company’s stock, valued at $899,197.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.30% of the company’s stock.

Large investors have recently modified their holdings of the company. AlphaOne Investment Services LLC boosted its stake in shares of AMAG Pharmaceuticals by 25.7% in the fourth quarter. AlphaOne Investment Services LLC now owns 66,105 shares of the specialty pharmaceutical company’s stock valued at $2,301,000 after buying an additional 13,500 shares during the period. New York State Teachers Retirement System boosted its stake in shares of AMAG Pharmaceuticals by 5.0% in the fourth quarter. New York State Teachers Retirement System now owns 25,325 shares of the specialty pharmaceutical company’s stock valued at $881,000 after buying an additional 1,200 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at about $17,870,000. Pacad Investment Ltd. purchased a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at about $425,000. Finally, Systematic Financial Management LP boosted its stake in shares of AMAG Pharmaceuticals by 124.1% in the fourth quarter. Systematic Financial Management LP now owns 156,440 shares of the specialty pharmaceutical company’s stock valued at $5,444,000 after buying an additional 86,645 shares during the period.

ILLEGAL ACTIVITY WARNING: “$157.92 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/157-92-million-in-sales-expected-for-amag-pharmaceuticals-inc-amag-this-quarter/1324522.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.